Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on March 5, 2021, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020. The call aims to provide insights into recent business developments and offers investors an opportunity to understand the company's progress. Imara is focused on developing IMR-687, a promising treatment for sickle cell disease and beta-thalassemia.

Positive

• Imara is advancing IMR-687, a potential disease-modifying treatment for sickle cell disease and beta-thalassemia.
• The upcoming conference call on March 5, 2021, presents a platform for discussing business progress and financial results.

Negative

• None.

BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, March 5, 2021 at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020 and review recent business highlights.

A live webcast will be available under “Events and Presentations” in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 1368162. A replay of the webcast will be archived on the Imara website following the presentation.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com

Media Contact:
Gina Nugent
Ten Bridge Communications
617-460-3579
gina@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What is Imara Inc.'s financial results announcement date?

Imara Inc. will announce its financial results on March 5, 2021.

What does IMRA focus on in terms of product development?

IMRA is focused on developing IMR-687, a treatment for sickle cell disease and beta-thalassemia.

How can investors access the Imara Inc. conference call?

Investors can access the conference call by dialing +1 (833) 519-1307 for U.S. domestic calls or (914) 800-3873 for international calls.

Where can I find the webcast for Imara's conference call?

The webcast will be available under 'Events and Presentations' in the Investors section of Imara's website.